Randomized Trialhigh evidence
Efficacy and Safety of Gefurulimab in Generalized Myasthenia Gravis: The PREVAIL Phase 3 Randomized Clinical Trial.
JAMA neurology·July 27, 2026·PMID 42507440
Why it mattersComplement inhibition is an established therapeutic strategy in AChR-Ab+ gMG, but current options require intravenous infusion. Gefurulimab offers a self-administered, once-weekly subcutaneous alternative that demonstrated rapid and sustained efficacy, potentially improving treatment convenience and adherence.
The papers that matter, first.
MedLit ranks the medical literature into a specialty feed with concise summaries, evidence-aware triage, and visual takeaways.
§
MedLit · Evidence, Distilled